FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Blueberries Medical Corporationwhich Begins Trading on the CSE.

Blueberries Medical Corp. (CSE: BBM) has commenced trading on the Canadian Securities Exchange under the ticker “BBM” after completing a reverse takeover of CDN MSolar Corp. Blueberries Cannabis is a producer of a medical grade cannabis extract. The Company operates outside of the Colombian capital of Bogota and exports products on the international market.

Blueberries Medical is seeking to become a large-scale producer of naturally grown premium-quality cannabis with its primary operations well situated in the Bogota savanna in central Colombia. Lead by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries has received all licences required for the cultivation, production, domestic distribution and international export of cannabidiol (CBD) and tetrahydrocannabinol-based (THC) medical cannabis. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the company to become a leading international supplier of naturally grown, processed and standardized medicinal-grade cannabis oil extracts and related products.

Earlier this November, cannabis advocates scored several important ballots wins on Election Day. Michigan was one of the states that voted to approve recreational use of cannabis and has now become the 10th legalized state in the U.S. In addition, Utah and Missouri legalized medical cannabis use. According to recent data published by New Frontier Data, the three new markets are projected to account for more than USD 1.2 Billion in additional sales for a combined total of USD 2.1 Billion in total legal sales by 2025. This increase will create more than 30,000 additional cannabis jobs over the same period. After the midterm elections, cannabis legalization, of some form, has occurred in about 60% of the country and based on New Frontier’s research, legal retail sales revenues are currently estimated to be USD 10.3 Billionin 2018.

Medical cannabis accounted for most of the market last year, with the pain management sub-segment holding around 75% of the medical market valuation, or USD 5.48 Million. With research and technology rapidly evolving in the medical cannabis market, regulators are expected to tone down restrictions. Now, after Utah and Missouri have moved to legalize medical cannabis, the move highlights the widespread appeal of the products. “The prospects for moving cannabis legislation are better if the House can pass bills,” Vivien Azer, a Cowen analyst covering the cannabis industry, told CNBC before the midterm results. “Given popular support for cannabis legislation and a preference by many Senate Republicans to respect state’s rights, a GOP Senate could advance a cannabis bill.”

For more information, please visit:Blueberries Medical Corp.

For more corporate news on WeedMD Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.